Pfizer at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Pfizer takes part in 3 sessions at ESMO 2026 in Madrid, and exhibits at Booth 8031. Its program centres on advanced non-small cell lung cancer, including seven-year trial results in first-line ALK-positive disease that point towards managing it as a chronic condition, and new antibody therapies. It also covers individualised treatment decisions in metastatic breast cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
Global pharmaceutical company whose oncology portfolio spans breast, lung, prostate, bladder and blood cancers, including antibody-drug conjugates from its Seagen acquisition. | Booth Exhibiting at Booth 8031 Satellite Sat Oct 24 13:00–14:30 Satellite Sat Oct 24 18:30–20:00 Pfizer - Breaking the Treatment Plateau in Advanced NSCLC: Antibody Therapy Redefined Lung & thoracic cancers Satellite Sun Oct 25 18:30–20:00 |
Instantly find 20 buyers from Pfizer
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction